DOJ, SEC Subpoenas Add to Biogen’s Compounding Problems | BioSpace

Quote


Next stop 196. Predictable bad decisions by leadership and always headed down.

It is actually amazing when you think how often they are wrong. Even random chance would do better and biib pays its lt likely 50M plus per year in total.

The perfect inverse Cramer within biotech. Watch biogen. Do the opposite (and dont partner). Succeed.
 


Write your reply...
Top Bottom
Back
Quote